Clinical Trials Logo
  1. Home
  2. Neoadjuvant Therapy
  3. NCT05406999

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Neoadjuvant Therapy Clinical Trial

Official title:
A Prospective, Multi-arm, Multi-center Clinical Trial on Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Clinical Trial Summary

This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.

Clinical Trial Description

The study was designed to evaluate the efficacy and safety of different forms of neoadjuvant intense androgen deprivation therapy (ADT) compared with ADT alone, followed by prostatectomy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05406999
Study type Interventional
Source The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Contact
Status Recruiting
Phase Phase 2
Start date February 1, 2020
Completion date June 30, 2030
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Not yet recruiting NCT05996484 - Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma Phase 2
Not yet recruiting NCT04520737 - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases N/A
Recruiting NCT06138496 - Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC Phase 2
Not yet recruiting NCT05983094 - Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer Phase 2
Terminated NCT04440982 - Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients Phase 2
Recruiting NCT04028375 - Study of CT and MR in the Gastric Cancer
Active, not recruiting NCT03192735 - Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT04588987 - Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma Phase 2
Not yet recruiting NCT05993858 - Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC Phase 2
Active, not recruiting NCT04666090 - Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma Phase 2
Recruiting NCT04848454 - Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy Phase 2
Recruiting NCT04062058 - A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT06124378 - Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer Phase 2
Not yet recruiting NCT06125223 - PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma
Recruiting NCT05371197 - Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer Phase 2
Recruiting NCT06212440 - Clinical Application of Multi-modal Sentinel Lymph Node Staining Method in Breast Cancer Patients After Neoadjuvant Chemotherapy N/A
Completed NCT03178032 - Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT02769104 - Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer Phase 3
Active, not recruiting NCT04986306 - The Validation of Sentinel Lymph Node Biopsy After Neo-adjuvant Chemotherapy in Breast Cancer Patients